2003PubMedRequires access

[Treatment of rheumatoid arthritis].

Đurđica Babić-Naglić

Open publisher page 0 citations

Abstract

Basic principles of drug treatment for rheumatoid arthritis are described. Nonsteroidal antirheumatic drugs are available and efficacious and part of almost each therapeutic approach. Corticosteroids have antiinflammatory and symptomatic properties with fast signs of improvement and potential anti-erosive action. Methotrexate, sulfasalazine, chloroquine, azathioprin, cyclosporin and leflunomide are the most frequently administered disease modifying antirheumatic drugs with delayed clinical effects. The biologic agents (anticytokines) offer new opportunities because they inhibit proinflammatory cytokines activity and very first stages of inflammation. Combination therapy of almost all drugs is eligible if it is efficacious and not increasing risk of adverse events. The outcome of rheumatoid arthritis is related to early diagnosis and early treatment with monitoring of efficacy and adverse events.

About this research paper

What this paper is about

Basic principles of drug treatment for rheumatoid arthritis are described. Nonsteroidal antirheumatic drugs are available and efficacious and part of almost each therapeutic approach. Corticosteroids have antiinflammatory and symptomatic properties with fast signs of improvement and potential anti-erosive action. Methotrexate, sulfasalazine, chloroquine, azathioprin, cyclosporin and leflunomide are the most frequently administered disease modifying antirheumatic drugs with delayed clinical effects. The biologic agents (anticytokines) offer new opportunities because they inhibit proinflammatory cytokines activity and very first stages of inflammation. Combination therapy of almost all drugs is eligible if it is efficacious and not increasing risk of adverse events. The outcome of rheumatoid arthritis is related to early diagnosis and early treatment with monitoring of efficacy and adverse events.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Basic principles of drug treatment for rheumatoid arthritis are described. Nonsteroidal antirheumatic drugs are available and efficacious and part of almost each therapeutic approach. Corticosteroids have antiinflammatory and symptomatic properties with fast signs of improvement and potential anti-erosive action. Methotrexate, sulfasalazine, chloroquine, azathioprin, cyclosporin and leflunomide are the most frequently administered disease modifying antirheumatic drugs with delayed clinical effects. The biologic agents (anticytokines) offer new opportunities because they inhibit proinflammatory cytokines activity and very first stages of inflammation. Combination therapy of almost all drugs is eligible if it is efficacious and not increasing risk of adverse events. The outcome of rheumatoid arthritis is related to early diagnosis and early treatment with monitoring of efficacy and adverse events.

Key concepts: Leflunomide, Medicine, Rheumatoid arthritis, Sulfasalazine, Methotrexate, Adverse effect, Antirheumatic drugs, Antirheumatic Agents

Related papers

Back to paper searchBrowse research topicsOriginal source
[Treatment of rheumatoid arthritis]. — Research Paper | ScholarLens